Healthy subjects
Conditions
Interventions
6-week intake of the test food
6-week intake of the placebo food
Sponsors
HUMA R&D CORP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects giving written informed consent 2.To examine an influence of a test food product on knee joint pain by selecting males and females of Japanese nationality aged 40 and over, below 75 who are aware of knee pain but have not received orthopedic treatm
Exclusion criteria
Exclusion criteria: 1.Currently seeing a doctor for treatment of knee joint pain 2.Currently in treatment with medication 3.Presence or previous history of allergy to medication and/or food (especially, shrimps and crabs) 4.Presence or previous history of a severe disorder(s) such as diabetes, a circulatory disease, a hepatic disease, a renal disease, or a cardiac disease 5.Currently in treatment of rheumatism 6.Previous history of knee surgery 7.Plan to undergo medical treatment on knees during the study 8.Underwent an intraarticular injection of hyaluronic acid within two weeks before the selection or intraarticular injection of steroids within three months before the selection 9.Diagnosed with a bone or joint-related diseases such as a bone fracture or a sprain within the past three months 10.Regular intake of a health food product that contains hyaluronic acid, glucosamine, chondroitin sulfate, quercetin glycoside, vitamin D, or amino-acid formulation, and the intention of consuming the product during the study 11.Regular intake of medication with an influence on the evaluation of this study (particularly, a pharmaceutical product that contains glucosamine, chondroitin sulfate, vitamin D, or amino-acid formulation, or a pharmaceutical product for treatment of osteoporosis) 12.Regular use of an assistive cane 13.Regular intake of warfarin (product names: Warfarin, Warin, Arefarin, Warfarin, etc.) for treatment of cerebral infarction, a cardiac disease, or the like 14.Nursing or pregnant, or desired to become pregnant during the study 15.Presence or previous history of psychiatric visits for depression, a sleep disorder, etc. 16.Determined by the investigator to be unsuitable for enrollment in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| JKOM survey | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS survey | — |
Countries
Japan
Contacts
Public ContactOchitani Daisuke
HUMA R&D CORP Clinical Development Division
Outcome results
None listed